Alkermes PLC reported data that suggest its drug for major depressive disorder in patients who don’t respond well to standard therapies will work. ALKS 5461 produced statistically significant improvement on three rating scales, compared to a placebo. A press release said ALKS 5461 reflects a new approach “based on modulation of opioid receptors in the brain and is designed as a non-addictive, oral, once-daily medicine.” Based in Ireland, Alkermes has a research center in Waltham.
April 18, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢